Compare NIC & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NIC | ZYME |
|---|---|---|
| Founded | 2000 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | N/A | 2017 |
| Metric | NIC | ZYME |
|---|---|---|
| Price | $129.31 | $26.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $145.33 | $28.50 |
| AVG Volume (30 Days) | 121.4K | ★ 1.9M |
| Earning Date | 01-20-2026 | 11-06-2025 |
| Dividend Yield | ★ 0.99% | N/A |
| EPS Growth | ★ 18.84 | N/A |
| EPS | ★ 9.34 | N/A |
| Revenue | ★ $375,962,000.00 | $134,481,000.00 |
| Revenue This Year | N/A | $64.45 |
| Revenue Next Year | $5.09 | $67.04 |
| P/E Ratio | $13.88 | ★ N/A |
| Revenue Growth | 9.68 | ★ 116.21 |
| 52 Week Low | $97.90 | $9.03 |
| 52 Week High | $141.92 | $28.49 |
| Indicator | NIC | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 60.37 | 68.38 |
| Support Level | $124.79 | $24.83 |
| Resistance Level | $130.39 | $28.49 |
| Average True Range (ATR) | 2.91 | 1.57 |
| MACD | 0.96 | 0.15 |
| Stochastic Oscillator | 92.08 | 70.98 |
Nicolet Bankshares Inc is a United States-based bank holding company's principal business is banking, consisting of lending and deposit gathering, as well as ancillary banking-related products and services, to businesses and individuals of the communities it serves, and the operational support to deliver, fund and manage. It offers a variety of loans, deposits, and related services to business customers especially small and medium-sized businesses and professional concerns, business deposit products, cash management services, international banking services, business loans, lines of credit, commercial real estate financing, construction loans, agricultural real estate or production loans, and letters of credit, as well as retirement plan services.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.